Assembly Biosciences has dosed the first two participants in a Phase 2 study of ABI-6250, an oral small-molecule drug for chronic hepatitis delta virus (HDV) infection. The study will enroll about 80 participants to evaluate safety, pharmacokinetics, and antiviral efficacy, with initial data expected in late 2027. ABI-6250 aims to provide a convenient oral alternative to the current injectable treatment, potentially improving patient outcomes in this severe liver disease. The study is part of a collaboration with Gilead Sciences, which may license the drug after Phase 2.
Gilead Sciences (GILD) shares are trading at USD 169.20 with a strong 1-day gain of 6.28% as of Oct 30, 2026 03:12 WIB on Pluang. This positive movement contrasts with its typical hold time of 114 days, indicating increased short-term interest possibly linked to the news about the ABI-6250 Phase 2 study. The stock also offers a dividend yield of 2.06%, while the majority of Pluang users (81%) are buying rather than selling the shares.
